ATS 2024 Final Program

Click on the session title to view the speakers

290

TUESDAY • MAY 21

Medical Knowledge modules. This symposium is intended to help clinicians stay up to date with important information relevant to their medical practices, and to provide an opportunity for clinicians to evaluate their individual knowledge and skills while earning MOC Medical Knowledge points 2:15 "The Rhythm is Gonna Get You": Managing Unstable Arrythmias in the ICU 2:40 "Under Pressure": Use of Vasopressors for Hemodynamic Support 3:10 "Total Eclipse of the Heart": Management of PE and RV Failure 3:35 Question and Answer

understanding of (and knowledge gaps in) disease mechanisms, recent advances in management and ongoing/ future research endeavors on pulmonary sarcoidosis and APS. 2:15 Demographics and Disparities in Pulmonary Sarcoidosis 2:30 Inflammation and Anti-Inflammatory Treatment in Pulmonary Sarcoidosis 2:45 Fibrosis in Pulmonary Sarcoidosis 3:00 Sarcoidosis Associated Pulmonary Hypertension (SAPH) 3:15 Lung Transplantation and Holistic Care in APS CLINICAL • TRANSLATIONAL CLINICAL TOPICS IN PULMONARY MEDICINE C82 PRO CON DEBATE ON PROGRESSIVE PULMONARY FIBROSIS: IMPROVING UNDERSTANDING OF A DISEASE PHENOTYPE Assembly on Clinical Problems 2:15 p.m. - 3:45 p.m. Marriott Marquis San Diego Marina Grand Ballroom 8-9 (Lobby Level, North Tower) Target Audience ILD clinicians, physician-scientists, and clinical and industry trialists Objectives At the conclusion of this session, the participant will be able to: • understand and discuss the impact of PPF in clinical care • understand and discuss the extent to which precision medicine can predict or allow for early identification of PPF • understand the benefits and challenges of defining clinical trial populations using the PPF phenotype Progressive pulmonary fibrosis (PPF) designates a subset of fibrotic ILDs with a shared phenotype - characterized by irreversible progression, worsening respiratory symptoms, declining lung function, and premature mortality. PPF was included in the most recent international clinical practice guidelines and has been used as inclusion criteria in clinical 3:30 Panel Discussion and Q/A Session 1 3:35 Panel Discussion and Q/A Session 2 3:40 Panel Discussion and Q/A Session 3

CLINICAL CLINICAL TOPICS IN PULMONARY MEDICINE

C81 CURRENT AND EVOLVING

STRATEGIES FOR MANAGEMENT OF PULMONARY SARCOIDOSIS

Assembly on Clinical Problems 2:15 p.m. - 3:45 p.m.

Marriott Marquis San Diego Marina Pacific Ballroom 21-22 (Ground Floor, North Tower)

Target Audience All providers including physicians, trainees, allied health professionals and advanced practice providers who care for patients with sarcoidosis. Objectives At the conclusion of this session, the participant will be able to: • describe the health disparities that persist in the field of sarcoidosis • review recent insights on pathophysiology of pulmonary sarcoidosis • discuss available therapeutic options and future research in pulmonary sarcoidosis and advanced pulmonary sarcoidosis The majority of patients with pulmonary sarcoidosis have a good prognosis but a small subset progress to severe disease described as Advanced Pulmonary Sarcoidosis (APS). The variable nature of this disease and lack of understanding of the reasons of this variability make management of pulmonary sarcoidosis challenging. There needs to better recognition of different (and especially progressive and severe) disease patterns and effective management strategies of pulmonary sarcoidosis and APS. We will discuss current

ATS 2024 Conference Program • San Diego, CA